Drug Profile
Eritoran - Eisai Co Ltd
Alternative Names: B-1287; E-5564; Eritoran tetrasodiumLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Eisai Co Ltd
- Class Anti-infectives; Anti-inflammatories; Disaccharides; Sugar phosphates
- Mechanism of Action Endotoxin inhibitors; Lipid A inhibitors; Toll-like receptor 4 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Immunological disorders; Reperfusion injury; Septic shock
Most Recent Events
- 18 Aug 2022 Discontinued - Phase-III for Immunological disorders in Japan (IV) (Eisai pipeline, August 2022)
- 18 Aug 2022 Discontinued - Phase-III for Immunological disorders in USA (IV) (Eisai pipeline, August 2022)
- 19 May 2022 Eisai terminates a phase III REMAP-COVID trial in COVID-2019 infections in USA due to changes in the COVID-19 landscape (NCT02735707)